<DOC>
	<DOC>NCT02706886</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ALN-GO1 in healthy adult volunteers and subjects with PH1.</brief_summary>
	<brief_title>Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria, Primary</mesh_term>
	<criteria>Inclusion Criteria for Parts A and B: Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Willing to provide written informed consent and to comply with study requirements. Additional Inclusion Criteria for Part B: Confirmation of PH1 disease Meet 24 hour urine oxalate excretion requirements Estimated GFR of &gt;45 mL/min/1.73m2. If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days Exclusion Criteria for Parts A and B: No clinically significant health concerns (with the exception of PH1 for patients in Part B) Clinically significant ECG abnormalities Abnormal for AST/ALT and any other clinical safety laboratory result considered clinically significant Received an investigational agent within 3 months before the first dose of study drug or are in followup of another clinical study Known history of allergic reaction to an oligonucleotide or GalNAc History of intolerance to subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PH1</keyword>
	<keyword>Primary Hyperoxaluria</keyword>
	<keyword>RNAi therapeutic</keyword>
	<keyword>siRNA</keyword>
	<keyword>AGT</keyword>
</DOC>